LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

Search

AbbVie Inc

Fermé

Secteur Soins de santé

173.38 0.68

Résumé

Variation du prix de l'action

24h

Actuel

Min

172.04

Max

174.38

Chiffres clés

By Trading Economics

Revenu

547M

1.4B

Ventes

-2B

12B

P/E

Moyenne du Secteur

42.514

79.786

BPA

2.31

Marge bénéficiaire

11.121

Employés

50,000

EBITDA

-2.3B

4.5B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+9.37 upside

Dividendes

By Dow Jones

Prochains Résultats

25 juil. 2024

Date du Prochain Dividende

15 août 2024

Date du Prochain Détachement de Dividende

10 oct. 2024

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

815M

298B

Ouverture précédente

172.7

Clôture précédente

173.38

Sentiment de l'Actualité

By Acuity

45%

55%

116 / 369 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

AbbVie Inc Graphique

Actualités Associées

27 juin 2024, 13:58 UTC

Acquisitions, Fusions, Rachats

AbbVie Buys Celsius Therapeutics for $250 Million

26 avr. 2024, 20:53 UTC

Principaux Mouvements du Marché

AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q

26 avr. 2024, 12:25 UTC

Résultats

AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises

25 mars 2024, 13:43 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie

25 mars 2024, 13:06 UTC

Acquisitions, Fusions, Rachats

AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million

27 juin 2024, 13:28 UTC

Acquisitions, Fusions, Rachats

AbbVie Acquires Celsius for $250 Million in Cash >ABBV

27 juin 2024, 13:28 UTC

Acquisitions, Fusions, Rachats

AbbVie: Celsius' Lead Asset Has Completed Phase 1 Study in Inflammatory Bowel Disease >ABBV

27 juin 2024, 13:26 UTC

Acquisitions, Fusions, Rachats

AbbVie Acquires Celsius Therapeutics >ABBV

23 mai 2024, 20:05 UTC

Acquisitions, Fusions, Rachats

AbbVie Completes Acquisition Of Landos Biopharma >ABBV LABP

7 mai 2024, 20:30 UTC

Actualités

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

26 avr. 2024, 13:03 UTC

Résultats

AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title -- IBD

26 avr. 2024, 12:04 UTC

Résultats

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop -- Barrons.com

26 avr. 2024, 11:41 UTC

Résultats

AbbVie 1Q Adjusted EPS Cut 8c by Acquired IPR&D, Milestones Expense >ABBV

26 avr. 2024, 11:40 UTC

Résultats

AbbVie Had Seen 2024 Adjusted EPS $10.97-$11.17 >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q Net $1.37B >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q U.S. HUMIRA Rev $1.77B >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q Global Skyrizi Rev $2.01B >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q Global IMBRUVICA Rev $838M >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.54B >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q International HUMIRA Rev $499M >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q EPS 77c >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q Adj EPS $2.31 >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie Sees FY Adj EPS $11.13-Adj EPS $11.33 >ABBV

26 avr. 2024, 11:35 UTC

Résultats

AbbVie 1Q Rev $12.31B >ABBV

19 avr. 2024, 16:43 UTC

Résultats

The Bad News Heading Into AbbVie's First-Quarter Earnings Report -- IBD

4 avr. 2024, 05:00 UTC

Actualités

Big Pharma Stocks Need a Rethink. Investors Keep -2-

4 avr. 2024, 05:00 UTC

Actualités

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake. -- Barrons.com

2 avr. 2024, 12:51 UTC

Résultats

Eli Lilly's Ozempic Competitors Face Risks. Why the Stock Has More Upside. -- Barrons.com

25 mars 2024, 12:51 UTC

Acquisitions, Fusions, Rachats

AbbVie in Deal to Acquire Landos Biopharma for $137.5M

25 mars 2024, 12:33 UTC

Acquisitions, Fusions, Rachats

AbbVie: Proposed Transaction Is Expected to Close in the Second Calendar Qtr of 2024 >ABBV

Comparaison

Variation de prix

AbbVie Inc prévision

Objectif de Prix

By TipRanks

9.37% hausse

Prévisions sur 12 Mois

Moyen 188.46 USD  9.37%

Haut 214 USD

Bas 172 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

15 ratings

12

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

169.91 / 176.68Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

116 / 369Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.